Development Roadmap
Affinity reagents development roadmap
MIP Discovery is building a suite of synthetic affinity reagents to advance the characterization of viral vectors. These reagents are being designed to allow leading Cell and Gene Therapy solution providers to deliver a new generation of analytical tools that will give deeper knowledge at an accelerated speed.
Future thinking
Over the next 9-12 months we are focused on lentivirus and AAV characterization, tackling issues such as the overestimation of viral titre and the demand for potency testing without the need for biological measurement systems. We will also be developing affinity reagents for safety and QC testing, covering contaminants such as PEI, endotoxin and host cell proteins.
During this time we will also develop our technology for use in affinity purification of viral vectors. We expect to have prototype affinity ligands available for bench-scale purification within the next 12-18 months, and are happy to partner with purification partners to demonstrate this technology in application.
